Authors: Gertler, SZ MacDonald, D Goodyear, M Forsyth, P Stewart, DJ Belanger, K Perry, J Fulton, D Steward, W Wainman, N Seymour, L

Citation: Sz. Gertler et al., NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94), ANN ONCOL, 11(3), 2000, pp. 315-318

Authors: Shepherd, FA Abratt, R Crino, L Green, M Sandler, A Steward, W Iglesias, J Anglin, G

Citation: Fa. Shepherd et al., The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer, LUNG CANC, 30(2), 2000, pp. 117-125

Authors: Cassidy, J Twelves, C Cameron, D Steward, W O'Byrne, K Jodrell, D Banken, L Goggin, T Jones, D Roos, B Bush, E Weidekamm, E Reigner, B

Citation: J. Cassidy et al., Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients, CANC CHEMOT, 44(6), 1999, pp. 453-460

Authors: Nielsen, OS Dombernowsky, P Mouridsen, H Crowther, D Verweij, J Buesa, J Steward, W Daugaard, S van Glabbeke, M Kirkpatrick, A Tursz, T

Citation: Os. Nielsen et al., High-dose epirubicin is not an alternative to standard-dose doxorubicin inthe treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group, BR J CANC, 78(12), 1998, pp. 1634-1639